Compare Gilead Sciences, Inc. (GILD) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Atlassian Corporation PLC — how do they compare? Gilead Sciences, Inc. trades at $133.4 (market cap $163.51B), while Atlassian Corporation PLC trades at $88.91 (market cap $23.29B). The key difference: Gilead Sciences, Inc. is far larger — about 7× Atlassian Corporation PLC's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| GILD | TEAM | |
|---|---|---|
Market Cap | $163.51B | $23.29B |
Sector | Health | Technology |
52-Week High | $155.80 | $203.00 |
52-Week Low | $108.22 | $57.15 |
Enterprise Value | $178.05B | $23.39B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Atlassian (TEAM) trades at $89.08, down 7.31% on the day, amid a mixed technical and fundamental backdrop. The stock shows bullish technical signals from moving averages and ADX indicators, while recent quarterly earnings have consistently beaten expectations. Revenue growth remains strong, reaching $5.22B in FY2025, though profitability remains negative with a -3.5% net income margin. The company continues to invest heavily in AI-powered collaboration tools, with its Service Collection surpassing $1B in annual recurring revenue.
Outlook appears cautiously optimistic with a consensus price target of $115.33 representing 29% upside potential. Analyst sentiment is strongly bullish with 30 Buy ratings and no Sell recommendations. Key risks include persistent unprofitability, high valuation multiples (P/S 3.89, P/B 26.49), and competitive pressures in the collaboration software space. The company's AI integration strategy and enterprise adoption provide growth catalysts, but margin improvement remains critical for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
